GC-2107
- Generic Name
- GC-2107
A Study to Access Safety, Tolerability, Pharmacokinetics(PK) and Pharmacodynamics(PD) of Orally Administered GCC-4401C in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2013-10-01
- Last Posted Date
- 2014-12-23
- Lead Sponsor
- Green Cross Corporation
- Target Recruit Count
- 46
- Registration Number
- NCT01954238
- Locations
- 🇺🇸
PAREXEL Internatonal, Early phase clinical unit _Los Angeles, California, United States
A Study to Assess Safety, Tolerability, and Pharmacokinetics of Orally Administered GCC4401C in Healthy Volunteers
- First Posted Date
- 2012-07-27
- Last Posted Date
- 2012-08-29
- Lead Sponsor
- Green Cross Corporation
- Target Recruit Count
- 48
- Registration Number
- NCT01651234
- Locations
- 🇺🇸
Quintiles Phase1 Unit, Overland Park, Kansas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath